BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 27913204)

  • 1. The selective Bcl-2 inhibitor venetoclax, a BH3 mimetic, does not dysregulate intracellular Ca
    Vervloessem T; Ivanova H; Luyten T; Parys JB; Bultynck G
    Biochim Biophys Acta Mol Cell Res; 2017 Jun; 1864(6):968-976. PubMed ID: 27913204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of STA-9090 (Ganetespib) and venetoclax (ABT-199) combination on apoptotic pathways in human cervical cancer cells.
    Karademir D; Özgür A
    Med Oncol; 2023 Jul; 40(8):234. PubMed ID: 37432531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cells with high BCL-2 expression induced by venetoclax impact anti-leukemic immunity "graft-versus-leukemia effects".
    Nagasaki J; Nishimoto M; Koh H; Okamura H; Nakamae M; Sakatoku K; Ido K; Kuno M; Makuuchi Y; Takakuwa T; Nakashima Y; Hino M; Nakamae H
    Blood Cancer J; 2024 May; 14(1):79. PubMed ID: 38744860
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor.
    Salem AH; Menon RM
    Clin Transl Sci; 2024 May; 17(5):e13807. PubMed ID: 38778732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systems analysis of phosphorylation-regulated Bcl-2 interactions establishes a model to reconcile the controversy over the significance of Bcl-2 phosphorylation.
    Song T; Wang P; Yu X; Wang A; Chai G; Fan Y; Zhang Z
    Br J Pharmacol; 2019 Feb; 176(3):491-504. PubMed ID: 30500985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2.
    Guo Y; Xue H; Hu N; Liu Y; Sun H; Yu D; Qin L; Shi G; Wang F; Xin L; Sun W; Zhang F; Song X; Li S; Wei Q; Guo Y; Li Y; Liu X; Chen S; Zhang T; Wu Y; Su D; Zhu Y; Xu A; Xu H; Yang S; Zheng Z; Liu J; Yang X; Yuan X; Hong Y; Sun X; Guo Y; Zhou C; Liu X; Wang L; Wang Z
    J Med Chem; 2024 May; 67(10):7836-7858. PubMed ID: 38695063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YL064 activates proteasomal-dependent degradation of c-Myc and synergistically enhances the anti-tumor activity of ABT-199 in diffuse large B cell lymphoma.
    Shan H; Cao Y; Xiao X; Liu M; Wu Y; Zhu Q; Xu H; Lei H; Yao Z; Wu Y
    Signal Transduct Target Ther; 2020 Jul; 5(1):116. PubMed ID: 32632092
    [No Abstract]   [Full Text] [Related]  

  • 8. Steroid-free combination of 5-azacytidine and venetoclax for the treatment of multiple myeloma.
    Flanagan L; Coughlan A; Cosgrove N; Roe A; Wang Y; Gilmore S; Drozdz I; Comerford C; Ryan J; Minihane E; Parvin S; O'Dwyer M; Quinn J; Murphy P; Furney S; Glavey S; Chonghaile TN; ; ;
    Haematologica; 2024 Mar; ():. PubMed ID: 38511268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bax transmembrane domain interacts with prosurvival Bcl-2 proteins in biological membranes.
    Andreu-Fernández V; Sancho M; Genovés A; Lucendo E; Todt F; Lauterwasser J; Funk K; Jahreis G; Pérez-Payá E; Mingarro I; Edlich F; Orzáez M
    Proc Natl Acad Sci U S A; 2017 Jan; 114(2):310-315. PubMed ID: 28028215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.
    Montero J; Stephansky J; Cai T; Griffin GK; Cabal-Hierro L; Togami K; Hogdal LJ; Galinsky I; Morgan EA; Aster JC; Davids MS; LeBoeuf NR; Stone RM; Konopleva M; Pemmaraju N; Letai A; Lane AA
    Cancer Discov; 2017 Feb; 7(2):156-164. PubMed ID: 27986708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib.
    Young AI; Law AM; Castillo L; Chong S; Cullen HD; Koehler M; Herzog S; Brummer T; Lee EF; Fairlie WD; Lucas MC; Herrmann D; Allam A; Timpson P; Watkins DN; Millar EK; O'Toole SA; Gallego-Ortega D; Ormandy CJ; Oakes SR
    Breast Cancer Res; 2016 Dec; 18(1):125. PubMed ID: 27931239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The BH4 domain of Bcl-2 orthologues from different classes of vertebrates can act as an evolutionary conserved inhibitor of IP
    Ivanova H; Luyten T; Decrock E; Vervliet T; Leybaert L; Parys JB; Bultynck G
    Cell Calcium; 2017 Mar; 62():41-46. PubMed ID: 28179071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular BAPTA directly inhibits PFKFB3, thereby impeding mTORC1-driven Mcl-1 translation and killing MCL-1-addicted cancer cells.
    Sneyers F; Kerkhofs M; Speelman-Rooms F; Welkenhuyzen K; La Rovere R; Shemy A; Voet A; Eelen G; Dewerchin M; Tait SWG; Ghesquière B; Bootman MD; Bultynck G
    Cell Death Dis; 2023 Sep; 14(9):600. PubMed ID: 37684238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and Synthesis of Poly(2,2'-Bipyridyl) Ligands for Induction of Cell Death in Cancer Cells: Control of Anticancer Activity by Complexation/Decomplexation with Biorelevant Metal Cations.
    Balachandran C; Hirose M; Tanaka T; Zhu JJ; Yokoi K; Hisamatsu Y; Yamada Y; Aoki S
    Inorg Chem; 2023 Sep; 62(36):14615-14631. PubMed ID: 37642721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deregulated calcium signaling in blood cancer: Underlying mechanisms and therapeutic potential.
    Immanuel T; Li J; Green TN; Bogdanova A; Kalev-Zylinska ML
    Front Oncol; 2022; 12():1010506. PubMed ID: 36330491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric cross-talk between the hydrophobic cleft and the BH4 domain of Bcl-2 in control of inositol 1,4,5-trisphosphate receptor activity.
    Shapovalov G; Ritaine A; Essonghe NC; de Ridder I; Ivanova H; Karamanou S; Economou A; Bultynck G; Skryma R; Prevarskaya N
    Explor Target Antitumor Ther; 2022; 3(3):375-391. PubMed ID: 36045908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. iRhom pseudoproteases regulate ER stress-induced cell death through IP
    Dulloo I; Atakpa-Adaji P; Yeh YC; Levet C; Muliyil S; Lu F; Taylor CW; Freeman M
    Nat Commun; 2022 Mar; 13(1):1257. PubMed ID: 35273168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcl-xL acts as an inhibitor of IP
    Rosa N; Ivanova H; Wagner LE; Kale J; La Rovere R; Welkenhuyzen K; Louros N; Karamanou S; Shabardina V; Lemmens I; Vandermarliere E; Hamada K; Ando H; Rousseau F; Schymkowitz J; Tavernier J; Mikoshiba K; Economou A; Andrews DW; Parys JB; Yule DI; Bultynck G
    Cell Death Differ; 2022 Apr; 29(4):788-805. PubMed ID: 34750538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The multiple mechanisms of MCL1 in the regulation of cell fate.
    Widden H; Placzek WJ
    Commun Biol; 2021 Sep; 4(1):1029. PubMed ID: 34475520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcl-2-Protein Family as Modulators of IP
    Ivanova H; Vervliet T; Monaco G; Terry LE; Rosa N; Baker MR; Parys JB; Serysheva II; Yule DI; Bultynck G
    Cold Spring Harb Perspect Biol; 2020 Apr; 12(4):. PubMed ID: 31501195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.